secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACTUATE THERAPEUTICS, INC. (ACTU)
CIK:        0001652935
Form:       8-K
Filed at:   2026-05-22T20:43:53+00:00
Accession:  0001683168-26-004268
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Actuate Therapeutics holds 2026 Annual Meeting; elects Fletcher and Keyes as directors, ratifies Crowe LLP as auditor
--------------------------------------------------------------------------------

- Elected Aaron G.L. Fletcher, Ph.D. and Jason Keyes as Class II directors for three-year terms through 2029.
- Fletcher received 14,877,247 for, 1,883,025 withheld; Keyes received 16,727,875 for, 32,397 withheld.
- Ratified Crowe LLP as independent auditor for FY 2026 with 18,571,817 for, 50,023 against, 9,741 abstain.
- Broker non-votes: 1,871,309 on director elections; none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652935/000168316826004268/0001683168-26-004268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652935/000168316826004268/actuate_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-004268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer